James Allison

James Allison pioneered the concept of immune checkpoint blockade for cancer therapy by demonstrating that antibody-mediated blockade of CTLA-4 could unleash anti-tumor T cell immunity and cure established tumors in mice, leading to the development of ipilimumab and the 2018 Nobel Prize in Physiology or Medicine shared with Tasuku Honjo. His insight that releasing the brakes on the immune system rather than pressing the accelerator could achieve durable cancer regression transformed oncology. Ipilimumab became the first checkpoint inhibitor approved by the FDA in 2011, proving that immunotherapy could extend survival in metastatic melanoma. His conceptual framework of immune checkpoint blockade has generated a multibillion-dollar therapeutic class and saved hundreds of thousands of lives.